Capmatinib in Japanese patients with MET exon 14 skipping–mutated or MET‐amplified advanced NSCLC: GEOMETRY mono‐1 study

MET mutations leading to exon 14 skipping (METΔex14) are strong molecular drivers for non–small‐cell lung cancer (NSCLC). Capmatinib is a highly potent, selective oral MET inhibitor that showed clinically meaningful efficacy and a manageable safety profile in a global phase II study (GEOMETRY mono‐1...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Sci
Hauptverfasser: Seto, Takashi, Ohashi, Kadoaki, Sugawara, Shunichi, Nishio, Makoto, Takeda, Masayuki, Aoe, Keisuke, Moizumi, Sanae, Nomura, Satoshi, Tajima, Takeshi, Hida, Toyoaki
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2021
Schlagworte:
ORIGINAL ARTICLES
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8019204/
https://ncbi.nlm.nih.gov/pubmed/33506571
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14826
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge